Skip to main content

Mitral Inflow E/A Ratio by PW Doppler

Mitral Inflow E/A Ratio by Pulsed Wave Doppler


A Practical, Guideline-Based Approach



---


1. Introduction


Mitral inflow assessment using pulsed wave (PW) Doppler is a fundamental component of diastolic function evaluation. The E/A ratio reflects the relationship between early passive LV filling (E wave) and late filling due to atrial contraction (A wave).


It is simple to measure but frequently misinterpreted if age, heart rate, and complementary parameters are not considered.


Guidelines reference: ASE/EACVI Recommendations for the Evaluation of LV Diastolic Function (2016 update).



---


2. Physiology Behind E and A Waves


During diastole:


• Early rapid filling → E wave

• Diastasis → minimal flow

• Atrial contraction → A wave


Normal physiology:


Young adults: E > A (E/A > 1)


With aging: relaxation slows → E decreases, A increases




---


3. Correct Method of Measuring E/A Ratio


A. Image Acquisition


View: Apical 4-chamber

Doppler type: Pulsed Wave (PW)

Sample volume size: 1–3 mm


B. Correct Sample Volume Placement


Place the sample volume:


At the tips of the mitral valve leaflets


In diastole


Not too atrial


Not too ventricular



Incorrect placement results in:


Overestimation (too ventricular)


Underestimation (too atrial)



C. Doppler Settings


Align Doppler beam parallel to flow


Sweep speed: 50–100 mm/s


Optimize gain (clear envelope, no noise)


Measure peak velocities




---


4. How to Measure


1. Measure peak E velocity (m/s)



2. Measure peak A velocity (m/s)



3. Calculate:




E/A ratio = Peak E velocity / Peak A velocity


Always average over 3 beats (5 in atrial fibrillation not applicable as A absent).



---


5. Normal Values


Adults <60 years:


E/A: 1.0 – 2.0



Older adults:


May be <1 due to normal aging



E velocity:


Usually 0.6–1.3 m/s




---


6. Interpretation of E/A Ratio


E/A ratio alone is NOT sufficient. Always integrate with:


• Tissue Doppler e’

• E/e’ ratio

• LA volume index

• TR velocity



---


Grade I – Impaired Relaxation


E/A < 0.8


E velocity < 50 cm/s


Normal or low filling pressures



Common in:


Aging


Hypertension


LV hypertrophy




---


Grade II – Pseudonormal


E/A 0.8–2


Appears normal


Elevated filling pressures



Clues:


Reduced e’


Elevated E/e’


Enlarged LA



Requires Valsalva maneuver to unmask reversal.



---


Grade III – Restrictive Filling


E/A ≥ 2


Short deceleration time


High filling pressures



Seen in:


Advanced cardiomyopathy


Restrictive physiology


Acute decompensated HF




---


7. Important Pitfalls


• Tachycardia → E and A fusion

• Atrial fibrillation → no A wave

• Mitral stenosis → unreliable

• Significant MR → may elevate E

• High-output states → misleading patterns


Never interpret E/A in isolation.



---


8. Practical Clinical Algorithm (Simplified)


Step 1: Measure E/A

Step 2: If E/A <0.8 and E <50 cm/s → Grade I

Step 3: If E/A >2 → Grade III

Step 4: If between 0.8–2 → assess 3 parameters:


Average E/e’ >14


TR velocity >2.8 m/s


LA volume index >34 ml/m²



≥2 positive → elevated filling pressures



---


9. Key Take-Home Messages


• Proper sample placement is critical

• Age significantly influences E/A

• Pseudonormal pattern is common

• Always combine with tissue Doppler

• Follow ASE 2016 algorithm for accuracy


Comments

Popular posts from this blog

Brugada ECG vs Incomplete Right Bundle Branch Block (iRBBB)

Brugada ECG vs Incomplete Right Bundle Branch Block (iRBBB) Why this differentiation matters Brugada pattern is a malignant channelopathy associated with sudden cardiac death, while incomplete RBBB is usually a benign conduction variant. Mislabeling Brugada as iRBBB can be fatal; overcalling iRBBB as Brugada can lead to unnecessary anxiety and ICD implantation. --- 1. Basic Definitions Brugada ECG Pattern Primary repolarization abnormality Genetic sodium-channel disorder Characteristic ST-segment elevation in V1–V3 Risk of ventricular fibrillation and sudden death Incomplete RBBB (iRBBB) Depolarization abnormality Delay in right ventricular conduction Common in healthy individuals Usually asymptomatic and benign --- 2. ECG Morphology: Side-by-Side Comparison QRS Duration Brugada: QRS usually <120 ms iRBBB: QRS <120 ms, but with RBBB morphology --- V1–V2 Pattern (Key Differentiator) Brugada Pseudo-RBBB appearance ST elevation ≥2 mm ST segment is coved or saddleback Terminal QRS bl...

Acute Treatment of Hyperkalemia

Acute Treatment of Hyperkalemia – A Practical, Bedside-Oriented Guide Hyperkalemia is a potentially life-threatening electrolyte abnormality that demands prompt recognition and decisive management. The danger lies not only in the absolute potassium value but in its effects on cardiac conduction, which can rapidly progress to fatal arrhythmias. Acute treatment focuses on three parallel goals: stabilizing the cardiac membrane, shifting potassium into cells, and removing excess potassium from the body. Understanding this stepwise approach helps clinicians act quickly and rationally in emergency settings. Why Hyperkalemia Is Dangerous Potassium plays a key role in maintaining the resting membrane potential of cardiac myocytes. Elevated serum potassium reduces the transmembrane gradient, leading to slowed conduction, ECG changes, ventricular arrhythmias, and asystole. Importantly, ECG changes do not always correlate with potassium levels, so treatment decisions should be based on clinical c...

π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š

 π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š in  Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts.  The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.